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In this issue of PLoS Neglected Tropical
Diseases, Abdallah Daar and colleagues
describe the fourth independent external
analysis and evaluation of the Special
Programme for Research and Training
in Tropical Diseases (TDR) and summa-
rize the findings resulting from the review
[1]. The panel responsible for the review
and report, which was chaired by Daar,
recommends several critical areas of
refocus and reorganization and calls for
additional funding of TDR. In making its
recommendations, the panel considers the
changes that have taken place over the last
decade. The most notable change was the
unprecedented increase in funding, exter-
nal to TDR, for research and control of
tropical diseases and the accompanying
establishment of product development
partnerships (PDPs).
The panel contends that TDR should
increase its focus on research capacity
strengthening, concentrate on neglected
populations over neglected diseases, and
strengthen its role in transdisciplinary
research, particularly by augmenting its
capacity in social sciences. In spite of
TDR’s clear successes and accomplish-
ments since its inception, the panel
concludes that TDR has not kept pace
with a dynamic and changing world of
global health research. The panel also
concludes that TDR has not established
itself as a credible partner with other
leading funders, and is in danger of being
marginalized to the point of ineffectiveness
in addressing potentially critical gaps in
tropical disease research. The review
suggests that in its current form, TDR is
overly bureaucratic and poorly aligned
with the World Health Organization
(WHO), that it has insufficient funds and
flexibility to carry out its mandate, and
that it is not readily able to adapt to the
rapidly evolving and dynamic global
health landscape.
In order to ensure that TDR takes its
proper role in supporting research and
development (R&D) and training and to
capitalize on the tremendous support the
organization has among a broad constitu-
ency, especially among scientists in dis-
ease-endemic countries, the report recom-
mends that TDR focus its efforts in four
specific areas: (1) stewardship, (2) expand-
ed interventional research, (3) research
capacity strengthening, and (4) R&D for
physical products that are not otherwise
supported. In doing so, and with the
recognized need for substantial increases
in funding, TDR must dramatically re-
think its objectives and organization. It
should also focus efforts on improved
relationships with its sponsoring organiza-
tions and forge new interactions with
organizations, especially public–private
partnerships, with complementary inter-
ests in R&D and capacity building.
In their response to Daar and col-
leagues’ external review, Robert Ridley
(the Director of TDR) and colleagues
acknowledge many of the shortcomings
identified in the review, and say that TDR
has committed to a series of steps to
improve and reorganize based on the
evaluation’s recommendations [2]. These
steps include a revised strategic focus on
knowledge management, an increased
capacity building effort, and an enhanced
focus on neglected areas such as some
aspects of translational research. The
external review contributed to TDR’s
new Ten Year Strategy and Business Plan
approved by TDR’s Joint Coordinating
Board and endorsed by WHO.
To implement the new strategy, Ridley
et al. describe the development of ‘‘busi-
ness lines’’ such as ‘‘BL3: Lead Discovery
for Drugs’’ or ‘‘BL7: Accessible Quality
Assured Diagnostics.’’ These business lines
are supported by expert scientific advisory
committees, and by necessity the business
lines can be started or stopped depending
on circumstances and the needs of the
stakeholder community. It is envisioned
that this business line model will provide a
better means for TDR to make decisions
and to respond to changing priorities.
These business lines cover the full product
development pathway from basic research
through product development to research
for access to interventions. They are
viewed as a critical mechanism to decen-
tralize TDR into discrete functional units
(rather than to decentralize administra-
tively) that is more responsive to changing
environments and to the priorities of
TDR’s stakeholders. Ridley et al. correctly
point out that TDR has played a key role
in the establishment of PDPs, such as the
Medicines for Malaria Venture. However,
TDR’s influence in this area has been
overshadowed by others, and consequent-
ly TDR proposes to shift its focus from
supporting PDPs to other areas where it
can have greater influence and impact.
TDR has made major contributions to
the lives of those in the developing world
and has supported scores of students and
scientists from disease-endemic countries.
With funding from UNICEF, the United
Nations Development Programme, the
World Bank, and WHO, TDR is consid-
ered the developing world’s research arm.
It is uniquely positioned to identify key
areas in tropical disease research and
training that are not being met by other
funding agencies, and to seek to fill those
gaps either through direct funding or by
creating partnerships that leverage other
investments. In recent years, there has
been an increased recognition that the
scientists, public health workers, and
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tries should contribute to research priori-
ties. TDR is in a position to make these
voices heard in setting the priorities.
Although TDR has had successes assisting
in the establishment of PDPs, it has not
fared so well in partnering with other
donor agencies, and as such may be
moving toward marginalization at a time
when it could be playing a critical role in
filling important research, training, and
implementation gaps.
The establishment of business lines is
intended to functionally decentralize TDR
and make it more responsive to its
stakeholders. It will be important, howev-
er, to see how the business line concept is
functionalized, how lines are initiated and
terminated, how funding priorities are
made across business lines, and what
metrics will be established to measure the
progress toward each business line’s ob-
jectives. Are the business lines repackaged
programs, or are they truly a new means
of setting and managing research priori-
ties?
TDR’s strengths and successes will need
to be better marketed, and its credibility as
a major player in the donor community
will have to be strengthened. It will need
to actively seek to establish better and
more effective means to partner with
others. It will need to identify those areas
where it is uniquely positioned to make a
significant impact and determine the
measure of that success, both in terms of
its longstanding and broad reach in
partnership with the developing world
and its ability to extend the impact of the
efforts of other donors.
The global health community and
external landscape have changed dramat-
ically since the establishment of TDR in
1978. TDR has made positive contribu-
tions to these changes. One thing is
certain: the landscape will continue to
change as research provides new opportu-
nities to extend and improve the lives of
those in the developing world; as innova-
tions transition from bench to bedside; as
new and exciting partners recognize the
importance of contributing to the gargan-
tuan effort needed; as new scientists from
the developed and developing world enter
into the scene; and as the priorities of the
developing world change. TDR must be
given the strength, flexibility, and resourc-
es to play a major role in extending
progress in tropical disease research and
training.
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